

**Supplementary Table 1. Patient, disease and treatment characteristic differences based on statin use**

<b>Patient characteristics</b>	<b>Statin at or prior to diagnosis</b>	<b>No statin at or prior to diagnosis</b>	<b><i>p</i></b>
<b>Age, years</b>			
Mean (SD)	73 (11)	68 (12)	0.003
<b>Gender</b>			
Male	26 (44.1%)	121 (51.9%)	0.281
Female	33 (55.9%)	112 (48.1%)	
<b>Race</b>			
Caucasian	56 (98.2%)	211 (95.0%)	0.288
Other	1 (1.8%)	11 (5.0%)	
<b>Body mass index</b>			
Mean (SD)	26.3 (6.0)	25.3 (4.7)	0.175
<b>Comorbidities</b>			
Diabetes	41 (69.5%)	135 (57.9%)	0.105
Coronary artery disease	15 (25.4%)	22 (9.4%)	0.001
Hyperlipidemia	44 (74.6%)	29 (12.4%)	<0.001
Hypertension	50 (84.7%)	157 (67.4%)	0.009
<b>Medications</b>			
Metformin	15 (25.4%)	26 (11.2%)	0.005
Pancreatic enzymes	22 (37.3%)	108 (42.4%)	0.211
Sulfonylurea	8 (13.6%)	15 (6.4%)	0.070
Insulin	36 (61.0%)	122 (52.4%)	0.233
Glucocorticoid	22 (37.3%)	69 (29.6%)	0.256
Beta-blocker (before or at diagnosis)	16 (27.1%)	37 (15.9%)	0.045
Beta-blocker (active use)	21 (35.6%)	86 (36.9%)	0.851
<b>Disease characteristics</b>	<b>Statin at or prior to diagnosis</b>	<b>No statin at or prior to diagnosis</b>	<b><i>p</i></b>
<b>Lymph node status</b>			
cN0	22 (40.0%)	97 (42.9%)	0.694
cN+	33 (60.0%)	129 (57.1%)	
<b>Resectability</b>			
Unresectable	27 (47.4%)	115 (49.6%)	0.956
Borderline resectable	8 (14.0%)	31 (13.4%)	
Resectable	22 (38.6%)	86 (37.1%)	
<b>Treatment characteristics</b>	<b>Statin at or prior to diagnosis</b>	<b>No statin at or prior to diagnosis</b>	<b><i>p</i></b>
<b>Surgery</b>			
Yes	27 (45.8%)	106 (45.5%)	0.970
No	32 (54.2%)	127 (54.5%)	
<b>Immunotherapy</b>			
Yes	1 (1.7%)	10 (4.3%)	0.700
No	58 (98.3%)	223 (95.7%)	
<b>Chemotherapy</b>			
Yes	43 (72.9%)	196 (84.1%)	0.045

No	16 (27.1%)	37 (15.9%)	
----	------------	------------	--